Bristol-myers Squibb Compnay

Viiv Healthcare UK (no. 4) Limited

Britsol-myers Squibb Company

David Kenneth Leahy

Chung-Pin H Chen

Nicholas A Meanwell

John F Kadow

Tao Wang

Zhongxing Zhang

Kap-Sun Yeung

Yasutsugu Ueda

Timothy P Connolly

Nachimuthu Soundararajan

Shawn K Pack

Kathia Levesque

Pierre Sirard

Dominique Thoraval

Yu Fan

Lopa V Desai

Collin Chan

Sunil S Patel

Masano Sugiyama

Guanglin Luo

Ronald L Hanson

Chiajen Lai

Martin D Eastgate

Qi Gao

Bin Zheng

Lori Ann Spangler

Thomas E La Cruz

Scott A Savage

Jaan A Pesti

Gerard Crispino

Francis S Gibson

Francisco Gonzalez-Bobes

Matthew R Hickey

Thorsten Rosner

Paul C Lobben

Srividya Ramakrishnan

Joerg Deerberg

Thomas M Razler

John E Thornton

Anne I Song

Zhongmin Xu

Ye Zhu

Alina Borovika

Nathan R Domagalski

Chris Sfouggatakis

Maxime C D Soumeillant

Robert P Discordia

Rebecca A Green

Nathaniel David Kopp

Kathleen Lauser

Helen Y Luo

Venkatramana M Rao

Mourad Hamedi

Serge Zaretsky

Thomas L LaPorte

Jale Muslehiddinoglu

Michael David Bengt Fenster

Hong Geun Lee

Burcu Selin Aytar

Robert V Forest

This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein:  Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein:

Salts of prodrugs of piperazine and substituted piperidine antiviral agents

The invention generally relates to an improved process for the preparation of N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, 

Process for the preparation of N-((1R,2S,5R)-5-(-butylamino)-2-((S)-3-(7--butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrroldin-1-yl)cyclohexyl)acetamide

The disclosure generally relates to a process for the preparation of compounds of formula I, including synthetic intermediates which are useful in the process. 

Process for the preparation of cycloheptapyridine CGRP receptor antagonists

This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein:X is C or N with the proviso that when X is N, Rdoes not exist;W is C or N with the proviso that when W is N, Rdoes not exist;V is C;E is hydrogen or a pharmaceutically acceptable salt thereof; andY is selected from the group consisting of  Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein:L and M are independently selected from the group consisting of C-Calkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.

Prodrugs of piperazine and substituted piperidine antiviral agents

The disclosure generally relates to the novel compounds of formula I, including their salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD). 

CGRP receptor antagonists

The instant disclosure provides crystalline forms of 1-benzoyl-4-[2-[4,7-dimethoxy-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine, salts and solvates thereof. The present disclosure also generally relates to pharmaceutical compositions comprising the crystalline form(s), as well of methods of using the crystalline form(s) in the treatment of HIV and/or AIDS, and methods for obtaining such crystalline form(s).

[object Object]

The invention relates to an improved process for preparing [(1R), 2S]-2-aminopropionic acid 2-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-1-methylethyl ester of the formula:  Compound I has been shown to be useful for the treatment of certain types of cancer.

Process for the preparation of [(1R), 2S]-2-aminopropionic acid 2-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2, 1-F][1,2,4]triazin-6-yloxy]-1-methylethyl ester

Growing community of inventors

Hightstown, NJ, United States of America

David Kenneth Leahy